Workflow
Carisma Therapeutics (CARM)
icon
Search documents
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
Prnewswire· 2024-08-06 11:30
Company appoints renowned key opinion leaders in liver fibrosis, Scott Friedman, MD, and Ira Tabas, MD, PhD PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering c ...
Carisma Therapeutics Announces Changes to its Board of Directors
Prnewswire· 2024-07-01 11:30
Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander "Dr. Scadden's renowned expertise as a physician and medical researcher will be incredibly valuable to Carisma, and we are honored to welcome him to our Board of Directors. Ms. Thorell's experience as a public company executive and Board Member of biotech companies will enhance the business capabilities of our Board," said Steven Kelly, President and Chief Executive Officer of Carisma. "These new appointme ...
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
Prnewswire· 2024-06-27 20:30
Nomination triggers a $2 million milestone payment to Carisma The nomination of this Development Candidate leverages Carisma's expertise in engineering chimeric antigen receptor monocytes and macrophages ("CAR-M") with Moderna's mRNA and lipid nanoparticle platform to create a novel in vivo cell therapy for oncology. Pre-clinical data demonstrated that the Development Candidate can successfully create CAR-M directly in vivo, redirecting endogenous myeloid cells to attack cancer cells. Lin Guey, PhD, Chief S ...
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
Prnewswire· 2024-06-25 11:30
PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET. About Carisma Investors: Shveta Dighe Head of Investor Relations [email protected] SOURCE Carisma Therap ...
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Prnewswire· 2024-06-13 20:30
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY. Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer ...
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Prnewswire· 2024-05-16 11:30
CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT- 0525, an ex vivo gene-modified autologous chimeric antigen receptor-m ...
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research· 2024-05-09 13:36
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -24.32%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.52, delivering a surprise of 7.14%.Over the last four quarters, the company ha ...
Carisma Therapeutics (CARM) - 2024 Q1 - Quarterly Report
2024-05-09 11:52
See accompanying notes to unaudited interim consolidated financial statements. CARISMA THERAPEUTICS INC. Notes to the Interim Consolidated Financial Statements In late March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash to begin implementation in April 2024. The plan, includes several measures such as, including prioritizing CT0525, the Company's second product, as its lead anti-human epidermal growth factor receptor 2 ( ...
Carisma Therapeutics (CARM) - 2024 Q1 - Quarterly Results
2024-05-09 11:41
Exhibit 99.1 Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 First Quarter 2024 Highlights and Upcoming Milestones · CT-0508 (Anti-HER2 CAR-Macrophage) o In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing. o O ...
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Prnewswire· 2024-05-09 11:30
Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first quarter of 2025 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 Cash and cash equivalents of $56.5 million expected to fund the Company into the ...